If you take prescription drugs on Medicare, you may already have noticed that the dreaded “donut hole,” the coverage gap where your costs used to jump, has quietly stopped hitting your wallet the way it once did. That’s not an accident, and it isn’t going away. Starting with the plan year that opens January 1, 2027, the disappearance of that coverage gap becomes a permanent part of federal regulation for the first time, rather than something Medicare has been running on temporary instructions. The distinction matters more than it sounds, because it decides whether this protection can quietly lapse or has to stay in place unless Congress or a future rule changes it.
The Law That Started Closing the Donut Hole
The Inflation Reduction Act of 2022 rewrote the Medicare Part D drug benefit in stages. Among the biggest changes: it eliminated the old coverage gap phase, where enrollees who hit a certain spending level suddenly owed a much larger share of their drug costs, and it capped what beneficiaries pay once they reach catastrophic coverage. Those changes have already been rolling out. CMS’s April 2026 announcement of the Contract Year 2027 rule confirms what hasn’t happened until now: CMS writing the new benefit design into the actual Code of Federal Regulations.
Free retirement updates: Want plain-English help keeping more of your money in retirement? The free Retirement Shield newsletter covers the benefits, deadlines, and money mistakes that cost retirees, a couple times a week. Subscribe free.
Why This Had to Be Locked In by Regulation
Here’s the part most coverage of the drug-benefit redesign skips. When the Inflation Reduction Act passed, it told CMS to carry out the new Part D design through 2026 using program instructions, essentially detailed guidance letters to insurers rather than formal rules. That authority was always temporary. According to CMS’s own Contract Year 2027 final-rule fact sheet, with that program-instruction authority set to expire, the agency is now codifying the same benefit design, eliminating the coverage gap phase, establishing a reduced annual out-of-pocket threshold, and removing cost sharing for enrollees who reach the catastrophic phase, for 2027 and every plan year after it. In plain terms: the protection you may already be relying on was running on a temporary bridge, and this rule is what turns that bridge into permanent structure. It also matters for how future changes would have to happen. A program instruction can be revised or replaced with an internal memo. A regulation codified in the Code of Federal Regulations generally has to go through public notice and comment before it can be unwound, which is a higher and more visible bar.
What Actually Changes in the Codified Benefit
The mechanics of the redesigned benefit stay the same as what’s been phased in since 2025: instead of a coverage gap where cost sharing spikes partway through the year, enrollees move through their deductible and initial coverage phases and then reach a catastrophic phase where they owe nothing more for covered drugs for the rest of the plan year. CMS is not publishing new dollar thresholds for 2027 in this rule; those figures are calculated and released separately each year, the way the annual out-of-pocket cap and deductible have been in prior years. What the rule does is lock in the structure itself, so that a future administration cannot simply decline to renew a program instruction and let the coverage gap quietly reappear. For someone managing a fixed retirement income, that structural guarantee is arguably more useful than any single year’s dollar figure, since it means the redesigned benefit isn’t dependent on an annual paperwork renewal that could be skipped.
The Manufacturer Discount Program Takes the Old Discount Program’s Place
The rule also formally reflects a switch that already took effect on January 1, 2025: the Manufacturer Discount Program, in which drugmakers provide discounts on brand-name drugs during the initial coverage and catastrophic phases, replaced the old Coverage Gap Discount Program that existed when a true coverage gap still applied. CMS is codifying updates alongside it, including how True Out-of-Pocket costs are calculated, specialty-tier rules, and reinsurance payment methodology between the government, drug plans, and manufacturers, all designed to keep the redesigned benefit financially workable for insurers now that the gap itself is gone. CMS’s separate 2027 Part D bid announcement, released in July, notes that plan sponsors now have “sufficient experience under the redesigned Part D benefit” to price their 2027 plans without the temporary premium-smoothing help CMS had been offering since the redesign began, another sign the new structure is settling into the ordinary way Medicare drug plans are priced and regulated.
What This Means for Enrollees Starting January 1
For a Medicare beneficiary filling prescriptions, the day-to-day experience doesn’t change on January 1, 2027 the way it did when the redesign first phased in. What changes is durability. CMS’s own framing of this rule, part of a package it says will give beneficiaries “more reliable coverage” while keeping the system’s focus on patient outcomes, treats the closed coverage gap as a fixture of the program rather than a temporary policy choice. Barring a future rule or new legislation, Medicare beneficiaries filling prescriptions in 2027 and beyond will do so under a Part D benefit where the coverage gap phase no longer exists in the Code of Federal Regulations, not just in this year’s guidance letter.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
